DrugsControl Media Services
DrugsControl.org

News Detail

Immune therapy cancer drug Pembrolizumab and Nivolumab linked to heart risks in study (11-12-2020)

Copenhagen, 9 Dec 2020: Cancer patients who took immune therapies such as Merck & Co.’s Keytruda or Bristol-Myers Squibb Co.’s Opdivo showed a greater risk of developing heart problems in a View Details

Source : Hindustan Times

Related News